Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials • Transportation, E-Commerce & Mechanical Systems
5 pending office actions • 5 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 13 patents granted in the last 365 days
Instrumentation Laboratory Company is managing 4 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 4 distinct examiners, meaning that each pending case is being reviewed by a different person. This total lack of examiner overlap suggests that the company's prosecution results will depend on independent sets of examiner logic. Each case represents a unique interaction with the patent office staff.
The portfolio is spread across 4 distinct art units, matching the number of pending office actions and examiners. KAUR, GURPREET is the busiest examiner with 1 pending office action. Because there are distinct art units for the pending actions, each case is effectively isolated in its own technical and administrative silo. This high degree of dispersion requires a broad strategy to handle the various requirements of different art units simultaneously.
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (20%) |
| §103 only | 1 (20%) |
| Multi-statute (no §101) | 3 (60%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KAUR, GURPREET | 1 | 65.2% | +35.9% |
| KANAAN, MAROUN P | 1 | 62.6% | +31.7% |
| GOUGH, TIFFANY MAUREEN | 1 | 31.6% | +46.8% |
| TICHY, JENNIFER M.H. | 1 | 64.9% | +34.5% |
| MARCSISIN, ELLEN JEAN | 1 | 34.5% | +49.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 14663560 | BIOASSAY SYSTEM AND METHOD FOR DETECTING ANALYTES IN BODY FLUIDS | MARCSISIN, ELLEN JEAN | 139d overdue |
| 18528941 | BUILDING AND EXECUTING A MEDICAL ALGORITHM | KANAAN, MAROUN P | 41d |
| 18098422 | IDENTIFYING DIRECT ORAL FACTOR XA INHIBITORS | GOUGH, TIFFANY MAUREEN | 84d |
| 17150454 | LUPUS ANTICOAGULANT (LA) MIXING METHOD AND KIT WITH REDUCED FACTOR DEFICIENCY EFFECT AND REDUCED INHIBITOR INTERFERENCE FOR IDENTIFYING LA ASSOCIATED WITH ANTIPHOSPHOLIPID SYNDROME | TICHY, JENNIFER M.H. | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 14663560 | BIOASSAY SYSTEM AND METHOD FOR DETECTING ANALYTES IN BODY FLUIDS | MARCSISIN, ELLEN JEAN | 139d overdue |
| 18535453 | STABILIZING OXYGEN IN A COMPOSITION | KAUR, GURPREET | 16d |
| 18528941 | BUILDING AND EXECUTING A MEDICAL ALGORITHM | KANAAN, MAROUN P | 41d |
| 18098422 | IDENTIFYING DIRECT ORAL FACTOR XA INHIBITORS | GOUGH, TIFFANY MAUREEN | 84d |
| 17150454 | LUPUS ANTICOAGULANT (LA) MIXING METHOD AND KIT WITH REDUCED FACTOR DEFICIENCY EFFECT AND REDUCED INHIBITOR INTERFERENCE FOR IDENTIFYING LA ASSOCIATED WITH ANTIPHOSPHOLIPID SYNDROME | TICHY, JENNIFER M.H. | — |
| Art Unit | Apps |
|---|---|
| 1759 | 1 |
| 3687 | 1 |
| 1651 | 1 |
| 1653 | 1 |
| 1677 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18535453 | STABILIZING OXYGEN IN A COMPOSITION | KAUR, GURPREET | 1759 | §103 | Non-Final OA | 16d | Pending | Dec 11, 2023 |
| 18528941 | BUILDING AND EXECUTING A MEDICAL ALGORITHM | KANAAN, MAROUN P | 3687 | §101§103 | Final Rejection | 41d | Pending | Dec 05, 2023 |
| 18098422 | IDENTIFYING DIRECT ORAL FACTOR XA INHIBITORS | GOUGH, TIFFANY MAUREEN | 1651 | §103§112 | Non-Final OA | 84d | Pending | Jan 18, 2023 |
| 17150454 | LUPUS ANTICOAGULANT (LA) MIXING METHOD AND KIT WITH REDUCED FACTOR DEFICIENCY EFFECT AND REDUCED INHIBITOR INTERFERENCE FOR IDENTIFYING LA ASSOCIATED WITH ANTIPHOSPHOLIPID SYNDROME | TICHY, JENNIFER M.H. | 1653 | §103§112 | Non-Final OA | — | Pending | Jan 15, 2021 |
| 14663560 | BIOASSAY SYSTEM AND METHOD FOR DETECTING ANALYTES IN BODY FLUIDS | MARCSISIN, ELLEN JEAN | 1677 | §103§112 | Final Rejection | 139d overdue | Pending | Mar 20, 2015 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial